An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy
Source abstract
Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor with a high mortality rate. Immunotherapy has achieved promising clinical results in multiple cancers, but shows unsatisfactory outcome in GBM patients, and poor drug delivery across the blood-brain barrier (BBB) is believed to be one of the main limitations that hinder the therapeutic efficacy of drugs. Herein, a new cationic lipid nanoparticle (LNP) that can efficiently deliver siRNA across BBB and target mouse brain is prepared for modulating the tumor microenvironment for GBM immunotherapy. By designing and screening cationic LNPs with different ionizable amine headgroups, a lipid (named as BAMPA-O16B) is identified with an optimal acid dissociation constant (pKa) that significantly enhances the cellular uptake and endosomal escape of siRNA lipoplex in mouse GBM cells. Importantly, BAMPA-O16B/siRNA lipoplex is highly effective to deliver siRNA against CD47 and PD-L1 across the BBB into cranial GBM in mice, and downregulate target gene expression in the tumor, resulting in synergistically activating a T cell-dependent antitumor immunity in orthotopic GBM. Collectively, this study offers an effective strategy for brain targeted siRNA delivery and gene silencing by optimizing the physicochemical property of LNPs. The effectiveness of modulating immune environment of GBM could further be expanded for potential treatment of other brain tumors.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. Engineering challenges for brain tumor immunotherapy10.1016/j.addr.2017.06.006 ↗
2. Immunotherapy for glioma: current management and future application10.1016/j.canlet.2020.02.002 ↗
3. Neoadjuvant checkpoint blockade for cancer immunotherapy10.1126/science.aax0182 ↗
4. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma10.1186/s13046-019-1085-3 ↗
5. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet10.18632/oncotarget.21586 ↗
6. Blood-brain barrier permeability and physical exercise10.1186/s12974-019-1403-x ↗
7. Immunotherapy in CNS cancers: the role of immune cell trafficking10.1093/neuonc/noy084 ↗
8. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms10.1016/j.it.2005.07.004 ↗
9. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery10.1038/nrd.2015.21 ↗
10. Knocking down disease: a progress report on siRNA therapeutics10.1038/nrg3978 ↗
11. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials10.1016/j.lfs.2017.08.027 ↗
12. RNA interference-based cancer drugs: the roadblocks, and the "delivery" of the promise10.1089/nat.2018.0762 ↗
13. Carrier strategies boost the application of CRISPR/Cas system in gene therapy
14. Cation-free siRNA micelles as effective drug delivery platform and potent RNAi nanomedicines for glioblastoma therapy
15. Single siRNA nanocapsules for effective siRNA brain delivery and glioblastoma treatment10.1002/adma.202000416 ↗
16. Brain-targeted codelivery of Bcl-2/Bcl-xl and mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy10.1021/acsnano.2c00320 ↗
17. Elucidating the influences of size, surface chemistry, and dynamic flow on cellular association of nanoparticles made by polymerization-induced self-assembly10.1002/smll.201801702 ↗
18. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts10.1073/pnas.0805135105 ↗
19. Size and surface chemistry of nanoparticles lead to a variant behavior in the unfolding dynamics of human carbonic anhydrase10.1039/C5NR05360A ↗
20. Biological membrane-penetrating peptides: computational prediction and applications10.3389/fcimb.2022.838259 ↗
21. Nanoparticle surface charges alter blood-brain barrier integrity and permeability10.1080/10611860400015936 ↗
22. Nanoparticles' interactions with vasculature in diseases10.1039/C9CS00309F ↗
23. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier10.1016/S0022-3565(24)35204-8 ↗
24. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells10.1038/s41423-020-00572-w ↗
25. Intratumoral immunotherapy: using the tumor as the remedy10.1093/annonc/mdx683 ↗
26. The cutting-edge progress of immune-checkpoint blockade in lung cancer, Cell10.1038/s41423-020-00577-5 ↗
27. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors10.1126/scitranslmed.aaf2968 ↗
28. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer10.1111/imr.12527 ↗
29. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma10.1073/pnas.1721434116 ↗
30. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors10.1126/scitranslmed.aaf2968 ↗
31. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles10.1126/sciadv.aar2766 ↗
32. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles10.1002/adma.201902575 ↗
33. Imaging small molecule-induced endosomal escape of siRNA10.1038/s41467-020-15300-1 ↗
34. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape10.1038/nbt.2612 ↗
35. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids10.1038/sj.gt.3301506 ↗
36. Rational design of cationic lipids for siRNA delivery10.1038/nbt.1602 ↗
37. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells10.1016/S0021-9258(19)47429-2 ↗
38. Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions10.1021/la104590k ↗
39. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo10.1002/anie.201203263 ↗
40. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA10.1021/acsnano.8b01516 ↗
41. Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment10.1002/EXP.20210008 ↗
42. Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function10.1039/C9NR02297J ↗
43. Rigorous control of vesicle-forming lipid pK(a) by fluorine-conjugated bioisosteres for gene-silencing with siRNA10.1016/j.jconrel.2018.12.044 ↗
44. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy10.1021/acsnano.6b04268 ↗
45. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview10.2147/DDDT.S218708 ↗
46. Crossing the blood-brain barrier with nanoparticles10.1016/j.jconrel.2017.12.015 ↗
47. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation10.1083/jcb.123.5.1107 ↗
48. Epidermal SR-A complexes are lipid raft based and promote nucleic acid nanoparticle uptake10.1016/j.jid.2020.10.027 ↗
49. Design of abiotic polymer ligand-decorated lipid nanoparticles for effective neutralization of target toxins in the blood10.1039/D1BM00515D ↗
50. Lipid-based nanocarriers for siRNA delivery: challenges, strategies and the lessons learned from the DODAX: MO liposomal system10.2174/1389450119666180703145410 ↗
51. Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion10.1016/j.celrep.2018.07.062 ↗
52. Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9(+) T cells10.1126/sciadv.aax4690 ↗
53. Immunotherapy for malignant glioma: current status and future directions10.1016/j.tips.2019.12.003 ↗
54. Current state of immunotherapy for glioblastoma10.1038/s41571-018-0003-5 ↗
55. Genetically programmable fusion cellular vesicles for cancer immunotherapy10.1002/anie.202108342 ↗
56. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity10.1136/jitc-2021-003464 ↗
57. Detachable liposomes combined immunochemotherapy for enhanced triple-negative breast cancer treatment through reprogramming of tumor-associated macrophages10.1021/acs.nanolett.1c01210 ↗
58. PD-1 and its ligands in tolerance and immunity10.1146/annurev.immunol.26.021607.090331 ↗
59. Nanocarrier-based drug combination therapy for glioblastoma10.7150/thno.38147 ↗
60. First-in-Human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers10.1200/JCO.18.02018 ↗
61. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma, N10.1056/NEJMoa1807315 ↗
62. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial10.1002/cncr.33378 ↗
63. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial10.1001/jamaoncol.2020.1024 ↗
64. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma10.1038/s41591-018-0339-5 ↗
65. Inhibition of intrinsic coagulation improves safety and tumor-targeted drug delivery of cationic solid lipid nanoparticles10.1016/j.biomaterials.2017.11.040 ↗
66. Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting10.2147/IJN.S188016 ↗